Thalidomide BMS1 is used to treat multiple myeloma (a cancer of the bone marrow) in combination with the cancer medicines melphalan and prednisone in patients who have not been treated for multiple myeloma before. It is used in patients aged 65 years or over, and in younger patients if they cannot be treated with high-dose chemotherapy. Thalidomide BMS must be prescribed and dispensed according to a special programme put in place to prevent the exposure of unborn children to the medicine. It contains the active substance thalidomide. 1Initially known as Thalidomide Pharmion and subsequently as Thalidomide Celgene.
Therapeutic Indication
### Therapeutic indication Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
Therapeutic Area (MeSH)
ATC Code
L04AX02
ATC Item
thalidomide
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Thalidomide | N/A | 沙利度胺 |
EMA Name
Thalidomide BMS (previously Thalidomide Celgene)
Medicine Name
Thalidomide BMS (previously Thalidomide Celgene)
Aliases
N/ANo risk management plan link.
